Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21231


RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer. PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before surgery to remove the prostate in treating patients who have localized prostate cancer.

Study summary:

OBJECTIVES: - Compare biomarker modulation (prostaglandin levels) in tissue samples of patients with localized prostate cancer treated with neoadjuvant celecoxib vs placebo followed by prostatectomy. - Compare the effect of these regimens on angiogenic factors within the prostate in these patients. - Determine the pharmacokinetic and pharmacodynamic effects of celecoxib in these patients. - Compare the toxicity profiles of these regimens in these patients. - Compare the compliance of patients treated with these regimens. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral neoadjuvant celecoxib twice daily. - Arm II: Patients receive oral neoadjuvant placebo twice daily. Treatment in both arms continues for at least 4 weeks followed by prostatectomy. Patients are followed within 1 month and then at 3 months. PROJECTED ACCRUAL: A total of 60-70 patients (at least 30 per arm) will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following: - Gleason sum at least 7 - Prostate-specific antigen (PSA) at least 15 ng/mL - Clinical stage T2b or T2c (stage II) - Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45% - At least 3 positive core biopsies - Planned radical prostatectomy - No metastatic disease secondary to prostate cancer PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - WBC greater than 3,000/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin greater than 9 g/dL - No history of bleeding disorders Hepatic: - Bilirubin less than 1.5 mg/dL - AST/ALT less than 1.5 times upper limit of normal - No viral hepatitis Renal: - Creatinine no greater than 1.5 mg/dL OR - Creatinine clearance at least 50 mL/min Other: - No history of hypersensitivity and/or adverse reactions to salicylates - No allergy to sulfa-containing medications - No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer - No medical or psychiatric problem that would preclude study participation - No active infection - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior immunologic therapy for prostate cancer Chemotherapy: - At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: - No prior androgen ablation for prostate cancer - At least 4 weeks since prior hormonal therapy and recovered - At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids - No concurrent glucocorticoids Radiotherapy: - At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered Surgery: - See Disease Characteristics - At least 4 weeks since prior major surgery and recovered Other: - No prior investigational therapy for prostate cancer - No prior or concurrent chronic anticoagulants - No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib) - At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA) - At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs) - At least 24 hours since prior use and no concurrent use of any of the following: - Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole - No aspirin (100 mg/day) within 1 week prior to surgery - No concurrent addition of vitamins or herbal supplements



Primary Contact:

Study Chair
Michael A. Carducci, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Backup Contact:


Location Contact:

Baltimore, Maryland 21231
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.